Quick Answer
Prelude Therapeutics Inc reported Operating Income Loss of -$104.57 million for the year ending 2025.
- Prelude Therapeutics Inc showed an increase of +25.2% in Operating Income Loss from 2024 to 2025.
- This data is from Prelude Therapeutics Inc's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$6.88 million | Q1 2020: -$9.74 million | Q2 2020: -$11.44 million | Q3 2020: -$18.14 million | Q1 2021: -$21.97 million | Q2 2021: -$27.92 million | Q3 2021: -$30.84 million | Q1 2022: -$30.29 million | Q2 2022: -$29.46 million | Q3 2022: -$30.41 million | Q1 2023: -$29.12 million | Q2 2023: -$32.40 million | Q3 2023: -$33.39 million | Q1 2024: -$34.34 million | Q2 2024: -$37.16 million | Q3 2024: -$34.38 million | Q1 2025: -$34.61 million | Q2 2025: -$32.19 million | Q3 2025: -$20.42 million.
- Over the full 7 years of available data (2019 to 2025), Prelude Therapeutics Inc's Operating Income Loss has declined by 272.0%.
- Historical annual values: Fiscal year 2025: -$104.57 million | Fiscal year 2024: -$139.71 million | Fiscal year 2023: -$132.28 million | Fiscal year 2022: -$123.54 million | Fiscal year 2021: -$113.74 million | Fiscal year 2020: -$58.76 million | Fiscal year 2019: -$28.11 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: